Evidence map›Paper›PMID 40113928›Full record

ArticleScientific reports2025

Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.

Lukas Andereggen, Emanuel Christ, Andrea Stieger, Markus M Luedi, Markus Huber

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lukas Andereggen *Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland. lukas.andereggen@unibe.ch.
Emanuel Christ *Department of Endocrinology, Diabetes and Metabolism, University Hospital of Basel, Basel, Switzerland.
Andrea StiegerDepartment of Anaesthesiology and Pain Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Markus M LuediDepartment of Anaesthesiology and Pain Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Markus HuberDepartment of Anaesthesiology and Pain Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent trends in first-line transsphenoidal surgery (TSS) for prolactinoma patients aim to reduce long-term dependence on dopamine agonists (DA). Key factors linked to poor surgical outcomes include cavernous sinus invasiveness and high baseline serum prolactin (PRL) levels. Defining simple PRL threshold values to indicate invasiveness and inform treatment strategy is crucial. In this retrospective cohort study of 149 prolactinoma patients treated with first-line transsphenoidal surgery (TSS) or dopamine agonist (DA) therapy, we evaluated preoperative prolactin (PRL) levels and cavernous sinus invasion as factors associated with long-term remission. Bayesian modeling identified cohort-wide and gender-specific PRL thresholds associated with invasiveness. Preoperative PRL values strongly correlated with cavernous sinus invasion (AUROC = 0.95; 95% CI: 0.90-0.98). The cohort-wide PRL threshold was 431.9 µg/L (95% CI: 181.1-708.3 µg/L), with gender-specific thresholds of 280.8 µg/L (95% CI: 51.0-528.2 µg/L) for women and 1325.0 µg/L (95% CI: 667.2-2582.9 µg/L) for men. Female thresholds were lower and less affected by age and obesity, while male thresholds were influenced by these factors, particularly in young, obese men. These findings suggest that gender-specific PRL thresholds may be useful for improving specificity and sensitivity in identifying invasiveness, potentially aiding clinical decisions. Personalized treatment informed by preoperative biomarkers is essential for optimizing outcomes and reducing DA reliance, but it should be considered in conjunction with a comprehensive clinical evaluation.

Indexed as

Pituitary NeoplasmsProlactinProlactinomaAdultAgedBayes TheoremDopamine AgonistsFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesSex FactorsYoung AdultDopamine AgonistsProlactinDopamine agonistsFirst-line surgeryLong-term outcomeMachine learningPrediction modelingProlactinoma

Identifiers

PMID40113928
PMCPMC11926263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.